Cambrex Corp. (CBM) Tops Q3 EPS by 6c; FY16 Outlook Increased
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- S&P Global explores potential separation of Capital IQ business
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Cambrex Reports Third Quarter 2016 Financial Results
November 4, 2016 7:00 AM EDT- Sales increased 8% in the quarter, full year sales and profit guidance increased -
- Acquisition of North Carolina based PharmaCore completed -
- Conference call at 8:30 a.m. ET on November 4, 2016 -
EAST RUTHERFORD, N.J., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reports results for the third quarter ended September 30, 2016.
Highlights
Sales increased... More


